Updated from 7:41 a.m.
Stock futures moved lower on Thursday morning after another decline in weekly jobless claims and an increase in durable goods last month.
S&P 500 futures were down 0.22%, Dow Jones Industrial Average futures fell 0.22%, and Nasdaq futures declined 0.22%.
Orders for long-lasting goods in the U.S. in July increased 4.4%, the Commerce Department reported Thursday, the largest gain since last fall. Core durable orders increased 1.6%. The better-than-expected improvement signaled a recent downturn in manufacturing activity is coming to a close.
The number of new claims for unemployment benefits fell 1,000 to 261,000 in the week ended Aug. 20, the Labor Department said Thursday. The less-volatile four-week average declined by 1,250 to 264,000. Jobless claims have remained below the 300,000 mark for 77 straight weeks, the longest streak since 1970.
Prominent central bankers, finance ministers and economists from around the world will meet in Jackson Hole Thursday to discuss economic trends and monetary policy action.
Investors are most eager to hear from Federal Reserve Chair Janet Yellen, who will deliver a widely anticipated speech on Friday. Her comments will provide important context to the markets' outlook for interest rates. Yellen's comments will likely remain dovish and conservative, emphasizing data dependence for any future rate moves.
The chances of a September rate hike currently sit at 21%, according to CME Group fed funds futures. A rate hike in November has better chances at 41%.
In earnings news, HP (HPQ) - Get Free Report fell 7% in premarket trading as fourth-quarter forecasts disappointed. The printer company expects current-quarter earnings no higher than 37 cents a share, short of consensus estimates of 41 cents. Weak sales of its printers weighed on projections, even as notebook sales offset softer demand.
HP earned 48 cents a share on revenue of $11.9 billion in its third quarter. Analysts expected profit of 44 cents a share on revenue of $11.47 billion.
Workday (WDAY) - Get Free Report climbed 10% on a mixed second quarter. A net loss of 4 cents a share was double what analysts had expected, while revenue of $377.7 million beat estimates by $5 million Third-quarter sales guidance of $398 million to $400 million came in short of consensus of $401.3 million.
Phillips-Van Heusen (PVH) - Get Free Report was slightly lower even after topping quarterly profit estimates. The parent of brands Tommy Hilfiger and Calvin Klein earned $1.47 a share, up 18 cents from forecasts. Revenue climbed 4.3% to $1.94 billion, matching consensus.
Guess? (GES) - Get Free Report exceeded earnings estimates but missed sales forecasts in its recent quarter. The fashion brand earned 14 cents a share in its second quarter, 7 cents higher than expected. Revenue inched 0.2% lower to $545. million, coming in $5.5 million below expectations.
Williams-Sonoma (WSM) - Get Free Report reduced its full-year forecast with chief executive officer Laura Alber citing a "more cautious consumer." The home-goods retailer reported a 4.8% decline in comparable-brand sales at Pottery Barn, its largest brand by sales. Williams-Sonoma cut its annual earnings estimates to $3.35 to $3.55 a share, down from $3.50 to $3.65 a share.
Tiffany (TIF) - Get Free Report moved higher after reporting a mixed second quarter. The jeweler earned 84 cents a share, up from 81 cents in the year-ago quarter and 12 cents higher than estimates. Revenue fell short, falling 6% to $932 million and just falling shy of consensus. Worldwide same-store sales declined 8%.
Dollar General (DG) - Get Free Report fell 5% after reporting on a disappointing second quarter. The discount retailer earned $1.08 a share, a penny short of estimates, while revenue of $5.39 billion missed by $110 million. Dollar General reported same-store sales growth of 0.7%.
Mylan (MYL) - Get Free Report moved slightly higher after taking steps to reduce the cost of its EpiPen in the wake of criticism from Democratic presidential candidate Hillary Clinton. The drugmaker said it would take "immediate action" to make its allergy medicine more accessible, including doubling the eligibity for its patient assistance program and reducing the cost of the treatment. The cost of the treatment has increased fivefold since 2007.